Subscribe
shutterstock_2131242569_t_schneider-1
T. Schneider / Shutterstock.com
18 October 2022BiotechnologyCatherine Wycherley

Biotech wins $16.5 million in drug royalties dispute

Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the drug elsewhere.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis upholds MS drug patent at Fed Circ
4 January 2022   Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.
Big Pharma
Israel targets Teva over MS drug royalties
12 May 2022   The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Novartis upholds MS drug patent at Fed Circ
4 January 2022   Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.
Big Pharma
Israel targets Teva over MS drug royalties
12 May 2022   The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.

More on this story

Americas
Novartis upholds MS drug patent at Fed Circ
4 January 2022   Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.
Big Pharma
Israel targets Teva over MS drug royalties
12 May 2022   The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner